Patent · US Active

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

US11939397B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Michael DiDonato · San Diego, US
Christoph Erkel · Planegg, DE
Anna Galkin · Encinitas, US
Scott Glaser · San Diego, US
Klaus Felix Hartlepp · Munich, DE
Yong Jia · San Diego, US
Alexandra Kraus · Munich, DE
Christian Cho-Hua Lee · San Diego, US
Sarah Rue · San Diego, US
Jian Shi · Lexington, US
Xenia Wezler · Munich, DE

Key dates

Filing date	May 29, 2019
Grant date	Mar 26, 2024
Priority date	—
Expiry date	Dec 1, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.